APA (7th ed.) Citation

Núñez, K., Sandow, T., Burton, J., Hibino, M., Gimenez, J., Cohen, A., . . . Thevenot, P. (2025). Sustained AFP-L3 or DCP expression is associated with progression risk and inferior outcomes in unresectable hepatocellular carcinoma. Clinical & Experimental Medicine, 25(1), 1. https://doi.org/10.1007/s10238-025-01877-8

Chicago Style (17th ed.) Citation

Núñez, Kelley, Tyler Sandow, Jeff Burton, Mina Hibino, Juan Gimenez, Ari Cohen, Neil Mehta, and Paul Thevenot. "Sustained AFP-L3 or DCP Expression Is Associated with Progression Risk and Inferior Outcomes in Unresectable Hepatocellular Carcinoma." Clinical & Experimental Medicine 25, no. 1 (2025): 1. https://doi.org/10.1007/s10238-025-01877-8.

MLA (9th ed.) Citation

Núñez, Kelley, et al. "Sustained AFP-L3 or DCP Expression Is Associated with Progression Risk and Inferior Outcomes in Unresectable Hepatocellular Carcinoma." Clinical & Experimental Medicine, vol. 25, no. 1, 2025, p. 1, https://doi.org/10.1007/s10238-025-01877-8.